GlassScriptPhysician profile
Adam Bied
NPI 1104185586
$31,258.06
in general payments reported to CMS, 2019-2025
15 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $2,434 · 2023: $14K · 2024: $14K · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $5,564 · Consulting Fee: $3,105 · Travel and Lodging: $3,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,620.00 |
| Food and Beverage | $5,564.02 |
| Consulting Fee | $3,105.00 |
| Travel and Lodging | $3,042.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24,761.14 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,769.10 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,384.35 | 2022-2024 | Vraylar |
| Ironshore Pharmaceuticals INC. | $950.12 | 2021-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $553.61 | 2021-2023 | Rexulti |
| Lundbeck LLC | $460.19 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $298.53 | 2022-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $254.55 | 2022-2024 | Ingrezza |
| Braeburn INC. | $204.10 | 2025 | Brixadi |
| Axsome Therapeutics, INC. | $200.97 | 2022-2024 | Auvelity |
| Cequr Corporation | $135.54 | 2024 | Cequr Simplicity |
| Gilead Sciences, INC. | $123.97 | 2025 | Yeztugo |
| Corium, LLC | $104.28 | 2022-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $33.33 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $24.28 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bied listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.